Literature DB >> 33979202

Infection imaging using [18F]FDG-labelled white blood cell positron emission tomography-computed tomography.

Venkata Subramanian Krishnaraju1, Harmandeep Singh1, Rajender Kumar1, Sarika Sharma1, Bhagwant Rai Mittal1, Anish Bhattacharya1.   

Abstract

Localizing the sites of infection in the body is possible in nuclear medicine using a variety of radiopharmaceuticals that target different components of the infective and inflammatory cascade. Gamma(γ)-emitting agents such as [67Ga]gallium citrate were among the first tracers used, followed by development of positron-emitting tracers like 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG). Though these tracers are quite sensitive, they have limited specificity for infection due to their concentration in sites of non-infective inflammation. White blood cells (WBC) labelled with γ or positron emitters have higher accuracy for differentiating the infective processes from the non-infective conditions that may show positivity with tracers such as 18F-FDG. We present a pictorial review of potential clinical applications of PET/CT using 18F-FDG labelled WBC.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33979202      PMCID: PMC8173673          DOI: 10.1259/bjr.20201204

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.629


  18 in total

1.  Biodistribution and dosimetry of [(18)F]fluorodeoxyglucose labelled leukocytes in normal human subjects.

Authors:  Lee A Forstrom; W L Dunn; B P Mullan; J C Hung; V J Lowe; L M Thorson
Journal:  Nucl Med Commun       Date:  2002-08       Impact factor: 1.690

2.  The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography.

Authors:  S Osman; H J Danpure
Journal:  Int J Rad Appl Instrum B       Date:  1992-02

3.  Utility of PET/CT with fluorine-18-fluorodeoxyglucose-labeled autologous leukocytes for diagnosing diabetic foot osteomyelitis in patients with Charcot's neuroarthropathy.

Authors:  Ashu Rastogi; Anish Bhattacharya; Mahesh Prakash; Sarika Sharma; Bhagwant R Mittal; Niranjan Khandelwal; Anil Bhansali
Journal:  Nucl Med Commun       Date:  2016-12       Impact factor: 1.690

4.  PET with FDG-labeled leukocytes versus scintigraphy with 111In-oxine-labeled leukocytes for detection of infection.

Authors:  Josephine N Rini; Kuldeep K Bhargava; Gene G Tronco; Carol Singer; Russell Caprioli; Scott E Marwin; Hugh L Richardson; Kenneth J Nichols; Paul V Pugliese; Christopher J Palestro
Journal:  Radiology       Date:  2006-03       Impact factor: 11.105

5.  Imaging infection with 18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients.

Authors:  Nicolas Dumarey; Dominique Egrise; Didier Blocklet; Bernard Stallenberg; Myriam Remmelink; Véronique del Marmol; Gaëtan Van Simaeys; Frédérique Jacobs; Serge Goldman
Journal:  J Nucl Med       Date:  2006-04       Impact factor: 10.057

6.  Guidelines for the labelling of leucocytes with (99m)Tc-HMPAO. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine.

Authors:  Erik F J de Vries; Manel Roca; Francois Jamar; Ora Israel; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04       Impact factor: 9.236

Review 7.  Clinically proven radiopharmaceuticals for infection imaging: mechanisms and applications.

Authors:  Stanley J Goldsmith; Shankar Vallabhajosula
Journal:  Semin Nucl Med       Date:  2009-01       Impact factor: 4.446

Review 8.  Currently Available Radiopharmaceuticals for Imaging Infection and the Holy Grail.

Authors:  Ebru Salmanoglu; Sung Kim; Mathew L Thakur
Journal:  Semin Nucl Med       Date:  2018-03       Impact factor: 4.446

9.  Comparison of FDG and FDG-labeled leukocytes PET/CT in diagnosis of infection.

Authors:  S Yilmaz; A Aliyev; O Ekmekcioglu; M Ozhan; L Uslu; B Vatankulu; S Sager; M Halaç; K Sönmezoğlu
Journal:  Nuklearmedizin       Date:  2015-10-27       Impact factor: 1.379

10.  A kit formulation for the preparation of [89Zr]Zr(oxinate)4 for PET cell tracking: White blood cell labelling and comparison with [111In]In(oxinate)3.

Authors:  Francis Man; Azalea A Khan; Amaia Carrascal-Miniño; Philip J Blower; Rafael T M de Rosales
Journal:  Nucl Med Biol       Date:  2020-09-15       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.